| [February 14, 2012] |
 |
Chemed Reports Fourth-Quarter 2011 Results
CINCINNATI --(Business Wire)--
Chemed Corporation (Chemed) (NYSE:CHE), which operates VITAS
Healthcare Corporation (VITAS), the nation's largest provider of
end-of-life care, and Roto-Rooter, the nation's largest commercial and
residential plumbing and drain cleaning services provider, reported
financial results for its fourth quarter ended December 31, 2011, versus
the comparable prior-year period, as follows:
Consolidated operating results:
-
Revenue increased 4.2% to $350 million
-
GAAP Diluted EPS increased 33.7% to $1.31
-
Adjusted Diluted EPS increased 19.8% to $1.45
VITAS segment operating results:
-
Net Patient Revenue of $255 million, an increase of 5.1%
-
Average Daily Census (ADC) of 13,724, an increase of 4.9%
-
Admissions of 15,191, an increase of 2.8%
-
Net Income of $22.7 million, a decrease of 2.6%
-
Adjusted EBITDA of $40.0 million, a decrease of 5.2%
-
Adjusted EBITDA margin of 15.7%, a decrease of 171 basis points
Roto-Rooter segment operating results:
-
Revenue of $95.7 million, an increase of 1.8%
-
Unit-for-unit job count of 165,841, a decrease of 0.2%
-
Net Income of $9.3 million, an increase of 27.6%
-
Adjusted EBITDA of $17.8 million, an increase of 12.0%
-
Adjusted EBITDA margin of 18.7%, an increase of 169 basis points
VITAS
Net revenue for VITAS was $255 million in the fourth quarter of 2011,
which is an increase of 5.1% over the prior-year period. Excluding the
impact of Medicare Cap, revenue increased 5.7%. This revenue growth was
the result of increased ADC of 4.9%, driven by an increase in admissions
of 2.8% and Medicare price increases of approximately 2.5%. This growth
was partially offset by geographic and level of acuity mix shift of the
patient base.
Average revenue per patient per day in the quarter, excluding the impact
of Medicare Cap, was $203.68, which is 0.7% above the prior-year period.
Routine home care reimbursement and high acuity care averaged $161.90
and $707.89, respectively, per patient per day in the fourth quarter of
2011. During the quarter, high acuity days of care were 7.6% of total
days of care, 27 basis points lower than the prior-year quarter.
In the fourth quarter of 2011, VITAS recorded a Medicare Cap liability
of $2.6 million. This compares to $1.1 million of Medicare Cap liability
recorded in the fourth quarter of 2010. The government's Medicare Cap
fiscal year begins on September 29. The first quarter of a Medicare Cap
year has the potential to be volatile if a program experiences unusual
or seasonal admission and discharge patterns. Based upon actual January
2012 admissions, VITAS anticipates reversing a significant portion of
this Medicare Cap liability in the first quarter of 2012.
Of VITAS' 37 unique Medicare provider numbers, 32 provider numbers have
a Medicare Cap cushion of 10% or greater during the trailing
twelve-month period; two provider numbers have a Medicare Cap cushion
between 5% to 10%; and three provider numbers have a cap cushion between
0% and 5%. VITAS generated an aggregate cap cushion of $218 million
during the trailing twelve-month period.
The fourth quarter of 2011 gross margin, excluding the impact of
Medicare Cap, was 23.8%, which is a decline of 155 basis points from the
fourth quarter of 2010. This decline in margin is primarily the result
of increased costs related to the 2011 mandated physician visit for
recertification, expansion of our community liaison program, expansion
of losses in start-up locations, as well as increased costs associated
with expansion of inpatient units.
Selling, general and administrative expense was $18.3 million in the
fourth quarter of 2011, which is a decrease of 2.8% when compared to the
prior-year quarter. Adjusted EBITDA totaled $40.0 million in the
quarter, a decrease of 5.2% over the prior-year period. Adjusted EBITDA
margin, excluding the impact from Medicare Cap, was 16.6% in the quarter
which was 122 basis points below the prior-year quarter.
Roto-Rooter
Roto-Rooter's plumbing and drain cleaning business generated sales of
$95.7 million for the fourth quarter of 2011, an increase of 1.8% over
the prior-year quarter. This revenue growth was the result of a
combination of selective price increases and favorable mix shift,
partially offset by a slight decline in aggregate job count.
Unit-for-unit job count in the fourth quarter of 2011 declined 0.2% when
compared to the prior-year period. During the fourth quarter of 2011,
total residential jobs decreased 2.6%, as residential plumbing jobs
increased 5.6% and residential drain cleaning jobs decreased 6.6%, when
compared to the fourth quarter of 2010. Residential jobs represented 70%
of total job count in the quarter. Total commercial jobs increased 5.7%,
with commercial plumbing/excavation job count increasing 10.8% and
commercial drain cleaning increasing 4.3% when compared to the
prior-year quarter. The "All Other" residential and commercial job
category, which represents less than 2% of aggregate job count,
decreased 6.1%.
Roto-Rooter's gross margin was 45.4% in the quarter, a 228 basis point
increase when compared to the fourth quarter of 2010. Adjusted EBITDA in
the fourth quarter of 2011 totaled $17.8 million, an increase of 12.0%,
and the Adjusted EBITDA margin was 18.7% in the quarter, an increase of
169 basis points, when compared to the prior-year quarter.
Roto-Rooter continues to have periodic discussions with existing
franchisees to acquire franchise territories. Management will be highly
disciplined in terms of valuation, risk assessment and overall return on
investment of any potential acquisition. The timing or actual completion
of any acquisition cannot be predicted.
Chemed Consolidated Debt and Cash Flows
Chemed had total debt of $167 million at December 31, 2011. This debt is
net of the discount taken as a result of convertible debt accounting
requirements. Excluding this discount, aggregate debt is $187 million
and is due in May 2014. Chemed's total debt equates to less than one
times trailing twelve-month adjusted EBITDA.
In March 2011 Chemed replaced its existing credit facility with a new
Credit Agreement. Terms of this Credit Agreement consist of a five-year
$350 million revolving credit facility. The interest rate on this Credit
Agreement has a floating rate that is currently LIBOR plus 175 basis
points. This Credit Agreement provides Chemed with increased flexibility
in terms of acquisitions, share repurchases, dividends and other
corporate needs. In addition, an expansion feature is included in this
Credit Agreement that provides Chemed the opportunity to increase its
revolver and/or enter into term loans for an additional $150 million. At
December 31, 2011, this facility had approximately $321 million of
undrawn borrowing capacity after deducting $29 million for letters of
credit issued to secure the Company's workers' compensation insurance.
Capital expenditures in 2011 aggregated $29.6 million and compares to
depreciation and amortization during the same period of $29.5 million.
The Company increased its quarterly dividend from $0.14 to $0.16 per
share in the third quarter of 2011. In addition, the company has
purchased $144 million, or 2,602,513 shares, of Chemed stock in 2011. As
of December 31, 2011, $75.3 million is remaining under Chemed's
previously announced share repurchase program. Management will
continually evaluate cash utilization alternatives, including share
repurchase, debt repurchase, acquisitions and increased dividends to
determine the most beneficial use of available capital resources.
Guidance for 2012
VITAS expects to achieve full-year 2012 revenue growth, prior to
Medicare Cap, of 5.0% to 8.0%. Admissions in 2012 are estimated to
increase approximately 2.5% to 4.0% and full-year Adjusted EBITDA
margin, prior to Medicare Cap, is estimated to be 15.0% to 15.5%.
Effective October 1, 2011, Medicare increased the average hospice
reimbursement rates by approximately 2.5%. Our guidance assumes VITAS
will incur $5.0 million of estimated Medicare contractual billing
limitations for calendar year 2012.
Roto-Rooter expects to achieve full-year 2012 revenue growth of 4.0% to
5.0%. The revenue estimate is a result of increased pricing of
approximately 2%, a favorable mix shift to higher revenue jobs, with job
count growth estimated at 0% to 1.5%. Adjusted EBITDA margin for 2012 is
estimated in the range of 17.0% to 18.0%.
Based upon the above, management estimates 2012 earnings per diluted
share, excluding non-cash expense for stock options, the non-cash
interest expense related to the accounting for convertible debt and
other items not indicative of ongoing operations, will be in the range
of $5.35 to $5.55. This compares to Chemed's 2011 adjusted earnings per
diluted share of $4.78.
Conference Call
Chemed will host a conference call and webcast at 10 a.m., ET, on
Wednesday, February 15, 2012, to discuss the Company's quarterly results
and to provide an update on its business. The dial-in number for the
conference call is (866) 203-3436 for U.S. and Canadian participants and
(617) 213-8849 for international participants. The participant passcode
is 77396059. A live webcast of the call can be accessed on Chemed's
website at www.chemed.com
by clicking on Investor Relations Home.
A taped replay of the conference call will be available beginning
approximately 24 hours after the call's conclusion. It can be accessed
by dialing (888) 286-8010 for U.S. and Canadian callers and (617)
801-6888 for international callers and will be available for one week
following the live call. The replay passcode is 43136718. An archived
webcast will also be available at www.chemed.com.
Chemed Corporation operates in the healthcare field through its VITAS
Healthcare Corporation subsidiary. VITAS provides daily hospice services
to approximately 13,500 patients with severe, life-limiting illnesses.
This type of care is focused on making the terminally ill patient's
final days as comfortable and pain-free as possible.
Chemed operates in the residential and commercial plumbing and drain
cleaning industry under the brand name Roto-Rooter. Roto-Rooter provides
plumbing and drain service through company-owned branches, independent
contractors and franchisees in the United States and
Canada. Roto-Rooter also has licensed master franchisees in Indonesia,
Singapore, Japan, and the Philippines.
This press release contains information about Chemed's EBITDA, Adjusted
EBITDA and Adjusted Diluted EPS, which are not measures derived in
accordance with GAAP and which exclude components that are important to
understanding Chemed's financial performance. In reporting its operating
results, Chemed provides EBITDA, Adjusted EBITDA and Adjusted Diluted
EPS measures to help investors and others evaluate the Company's
operating results, compare its operating performance with that of
similar companies that have different capital structures and evaluate
its ability to meet its future debt service, capital expenditures and
working capital requirements. Chemed's management similarly uses EBITDA,
Adjusted EBITDA and Adjusted Diluted EPS to assist it in evaluating the
performance of the Company across fiscal periods and in assessing how
its performance compares to its peer companies. These measures also help
Chemed's management to estimate the resources required to meet Chemed's
future financial obligations and expenditures. Chemed's EBITDA, Adjusted
EBITDA and Adjusted Diluted EPS should not be considered in isolation or
as a substitute for comparable measures calculated and presented in
accordance with GAAP. We calculated Adjusted EBITDA Margin by dividing
Adjusted EBITDA by service revenue and sales. A reconciliation of
Chemed's net income to its EBITDA, Adjusted EBITDA and Adjusted Diluted
EPS is presented in the tables following the text of this press release.
Forward-Looking Statements
Certain statements contained in this press release and the accompanying
tables are "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. The words "believe,"
"expect," "hope," "anticipate," "plan" and similar expressions identify
forward-looking statements, which speak only as of the date the
statement was made. Chemed does not undertake and specifically disclaims
any obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events or
otherwise. These statements are based on current expectations and
assumptions and involve various risks and uncertainties, which could
cause Chemed's actual results to differ from those expressed in such
forward-looking statements. These risks and uncertainties arise from,
among other things, possible changes in regulations governing the
hospice care or plumbing and drain cleaning industries; periodic changes
in reimbursement levels and procedures under Medicare and Medicaid
programs; difficulties predicting patient length of stay and estimating
potential Medicare reimbursement obligations; challenges inherent in
Chemed's growth strategy; the current shortage of qualified nurses,
other healthcare professionals and licensed plumbing and drain cleaning
technicians; Chemed's dependence on patient referral sources; and other
factors detailed under the caption "Description of Business by Segment"
or "Risk Factors" in Chemed's most recent report on form 10-Q or 10-K
and its other filings with the Securities and Exchange Commission. You
are cautioned not to place undue reliance on such forward-looking
statements and there are no assurances that the matters contained in
such statements will be achieved.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CHEMED CORPORATION AND SUBSIDIARY COMPANIES
|
|
CONSOLIDATED STATEMENT OF INCOME
|
|
(in thousands, except per share data)(unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Three Months Ended
|
|
|
For the Years Ended
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
|
December 31,
|
|
|
|
|
|
|
|
|
|
2011
|
|
2010
|
|
|
2011
|
|
2010
|
|
Service revenues and sales
|
|
$
|
350,253
|
|
|
$
|
336,286
|
|
|
|
$
|
1,355,970
|
|
|
$
|
1,280,545
|
|
|
Cost of services provided and goods sold
|
|
|
248,366
|
|
|
|
235,262
|
|
|
|
|
970,484
|
|
|
|
906,016
|
|
|
Selling, general and administrative expenses (aa)
|
|
|
48,564
|
|
|
|
55,270
|
|
|
|
|
202,260
|
|
|
|
201,964
|
|
|
Depreciation
|
|
|
6,288
|
|
|
|
6,338
|
|
|
|
|
25,247
|
|
|
|
24,386
|
|
|
Amortization
|
|
|
1,009
|
|
|
|
950
|
|
|
|
|
4,252
|
|
|
|
4,657
|
|
|
|
|
Total costs and expenses
|
|
|
304,227
|
|
|
|
297,820
|
|
|
|
|
1,202,243
|
|
|
|
1,137,023
|
|
|
|
|
Income from operations
|
|
|
46,026
|
|
|
|
38,466
|
|
|
|
|
153,727
|
|
|
|
143,522
|
|
|
Interest expense
|
|
|
(3,628
|
)
|
|
|
(3,013
|
)
|
|
|
|
(13,888
|
)
|
|
|
(11,959
|
)
|
|
Other income/(expense)--net (bb)
|
|
|
(164
|
)
|
|
|
1,850
|
|
|
|
|
717
|
|
|
|
2,268
|
|
|
|
|
Income before income taxes
|
|
|
42,234
|
|
|
|
37,303
|
|
|
|
|
140,556
|
|
|
|
133,831
|
|
|
Income taxes
|
|
|
(16,529
|
)
|
|
|
(14,673
|
)
|
|
|
|
(54,577
|
)
|
|
|
(52,000
|
)
|
|
Net income
|
|
$
|
25,705
|
|
|
$
|
22,630
|
|
|
|
$
|
85,979
|
|
|
$
|
81,831
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings Per Share
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
1.34
|
|
|
$
|
1.00
|
|
|
|
$
|
4.19
|
|
|
$
|
3.62
|
|
|
|
|
Average number of shares outstanding
|
|
|
19,237
|
|
|
|
22,534
|
|
|
|
|
20,523
|
|
|
|
22,587
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted Earnings Per Share
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
1.31
|
|
|
$
|
0.98
|
|
|
|
$
|
4.10
|
|
|
$
|
3.55
|
|
|
|
|
Average number of shares outstanding
|
|
|
19,556
|
|
|
|
23,070
|
|
|
|
|
20,945
|
|
|
|
23,031
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(aa)
|
|
Selling, general and administrative ("SG&A") expenses comprise (in
thousands):
|
|
|
|
|
|
|
|
|
|
For the Three Months Ended
|
|
|
For the Years Ended
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
|
December 31,
|
|
|
|
|
|
|
|
|
|
2011
|
|
2010
|
|
|
2011
|
|
2010
|
|
|
|
|
SG&A expenses before long-term incentive compensation and
the impact of market value gains of deferred compensation
plans
|
|
$
|
48,561
|
|
|
$
|
50,473
|
|
|
|
$
|
198,449
|
|
|
$
|
195,020
|
|
|
|
|
|
Market value gains on assets held in deferred compensation
trusts
|
|
|
3
|
|
|
|
1,862
|
|
|
|
|
799
|
|
|
|
2,210
|
|
|
|
|
|
Long-term incentive compensation
|
|
|
-
|
|
|
|
2,935
|
|
|
|
|
3,012
|
|
|
|
4,734
|
|
|
|
|
|
Total SG&A expenses
|
|
$
|
48,564
|
|
|
$
|
55,270
|
|
|
|
$
|
202,260
|
|
|
$
|
201,964
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(bb)
|
|
Other income/(expense)--net comprises (in thousands):
|
|
|
|
|
|
|
|
|
|
For the Three Months Ended
|
|
|
For the Years Ended
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
|
December 31,
|
|
|
|
|
|
|
|
|
|
2011
|
|
2010
|
|
|
2011
|
|
2010
|
|
|
|
|
Loss on disposal of property and equipment
|
|
$
|
(373
|
)
|
|
$
|
(132
|
)
|
|
|
$
|
(441
|
)
|
|
$
|
(425
|
)
|
|
|
|
|
Interest income
|
|
|
229
|
|
|
|
110
|
|
|
|
|
426
|
|
|
|
444
|
|
|
|
|
|
Market value gains on assets held in deferred compensation
trusts
|
|
|
3
|
|
|
|
1,862
|
|
|
|
|
799
|
|
|
|
2,210
|
|
|
|
|
|
Other
|
|
|
(23
|
)
|
|
|
10
|
|
|
|
|
(67
|
)
|
|
|
39
|
|
|
|
|
|
Total other income/(expense)--net
|
|
$
|
(164
|
)
|
|
$
|
1,850
|
|
|
|
$
|
717
|
|
|
$
|
2,268
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CHEMED CORPORATION AND SUBSIDIARY COMPANIES
|
|
CONSOLIDATED BALANCE SHEET
|
|
(in thousands, except per share data)(unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
|
|
|
|
|
|
|
|
|
2011
|
|
|
2010
|
|
Assets
|
|
|
|
|
|
|
|
|
|
|
|
|
Current assets
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
38,081
|
|
|
|
$
|
49,917
|
|
|
|
|
Accounts receivable less allowances
|
|
|
77,924
|
|
|
|
|
112,999
|
|
|
|
|
Inventories
|
|
|
8,668
|
|
|
|
|
7,728
|
|
|
|
|
Current deferred income taxes
|
|
|
12,540
|
|
|
|
|
15,098
|
|
|
|
|
Prepaid income taxes
|
|
|
2,131
|
|
|
|
|
770
|
|
|
|
|
Prepaid expenses
|
|
|
11,409
|
|
|
|
|
10,285
|
|
|
|
|
|
Total current assets
|
|
|
150,753
|
|
|
|
|
196,797
|
|
|
|
Investments of deferred compensation plans held in trust
|
|
|
31,629
|
|
|
|
|
28,304
|
|
|
|
Properties and equipment, at cost less accumulated depreciation
|
|
|
82,951
|
|
|
|
|
79,292
|
|
|
|
Identifiable intangible assets less accumulated amortization
|
|
|
58,262
|
|
|
|
|
57,858
|
|
|
|
Goodwill
|
|
|
460,633
|
|
|
|
|
458,343
|
|
|
|
Other assets
|
|
|
11,677
|
|
|
|
|
9,567
|
|
|
|
|
|
|
Total Assets
|
|
$
|
795,905
|
|
|
|
$
|
830,161
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities
|
|
|
|
|
|
|
|
|
|
|
|
|
Current liabilities
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accounts payable
|
|
$
|
48,225
|
|
|
|
$
|
55,829
|
|
|
|
|
Income taxes
|
|
|
90
|
|
|
|
|
1,161
|
|
|
|
|
Accrued insurance
|
|
|
37,147
|
|
|
|
|
36,492
|
|
|
|
|
Accrued compensation
|
|
|
41,087
|
|
|
|
|
39,719
|
|
|
|
|
Other current liabilities
|
|
|
18,851
|
|
|
|
|
16,141
|
|
|
|
|
|
Total current liabilities
|
|
|
145,400
|
|
|
|
|
149,342
|
|
|
|
Deferred income taxes
|
|
|
29,463
|
|
|
|
|
25,085
|
|
|
|
Long-term debt
|
|
|
166,784
|
|
|
|
|
159,208
|
|
|
|
Deferred compensation liabilities
|
|
|
30,693
|
|
|
|
|
27,851
|
|
|
|
Other liabilities
|
|
|
9,881
|
|
|
|
|
6,626
|
|
|
|
|
|
|
Total Liabilities
|
|
|
382,221
|
|
|
|
|
368,112
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders' Equity
|
|
|
|
|
|
|
|
|
|
|
|
|
Capital stock
|
|
|
30,937
|
|
|
|
|
30,382
|
|
|
|
Paid-in capital
|
|
|
398,094
|
|
|
|
|
365,007
|
|
|
|
Retained earnings
|
|
|
546,757
|
|
|
|
|
473,316
|
|
|
|
Treasury stock, at cost
|
|
|
(564,091
|
)
|
|
|
|
(408,615
|
)
|
|
|
Deferred compensation payable in Company stock
|
|
|
1,987
|
|
|
|
|
1,959
|
|
|
|
|
|
|
Total Stockholders' Equity
|
|
|
413,684
|
|
|
|
|
462,049
|
|
|
|
|
|
|
Total Liabilities and Stockholders' Equity
|
|
$
|
795,905
|
|
|
|
$
|
830,161
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CHEMED CORPORATION AND SUBSIDIARY COMPANIES
|
|
CONSOLIDATED STATEMENT OF CASH FLOWS
|
|
(in thousands)(unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Years Ended December 31,
|
|
|
|
|
|
|
|
|
|
|
|
|
2011
|
|
2010
|
|
Cash Flows from Operating Activities
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
85,979
|
|
|
$
|
81,831
|
|
|
|
Adjustments to reconcile net income to net cash provided by
|
|
|
|
|
|
|
|
|
|
|
|
operating activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
|
|
29,499
|
|
|
|
29,043
|
|
|
|
|
|
Provision for uncollectible accounts receivable
|
|
|
8,563
|
|
|
|
9,078
|
|
|
|
|
|
Stock option expense
|
|
|
8,376
|
|
|
|
7,762
|
|
|
|
|
|
Amortization of discount on convertible notes
|
|
|
7,576
|
|
|
|
7,081
|
|
|
|
|
|
Provision for deferred income taxes
|
|
|
7,242
|
|
|
|
(2,409
|
)
|
|
|
|
|
Noncash long-term incentive compensation
|
|
|
2,595
|
|
|
|
4,161
|
|
|
|
|
|
Amortization of debt issuance costs
|
|
|
1,137
|
|
|
|
654
|
|
|
|
|
|
Changes in operating assets and liabilities, excluding
|
|
|
|
|
|
|
|
|
|
|
|
|
|
amounts acquired in business combinations:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Decrease/(increase) in accounts receivable
|
|
|
26,896
|
|
|
|
(68,656
|
)
|
|
|
|
|
|
|
Increase in inventories
|
|
|
(940
|
)
|
|
|
(151
|
)
|
|
|
|
|
|
|
Decrease/(increase) in prepaid expenses
|
|
|
(1,124
|
)
|
|
|
332
|
|
|
|
|
|
|
|
Increase/(decrease) in accounts payable and other
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
current liabilities
|
|
|
(1,397
|
)
|
|
|
13,810
|
|
|
|
|
|
|
|
Increase in income taxes
|
|
|
2,708
|
|
|
|
4,825
|
|
|
|
|
|
|
|
Increase in other assets
|
|
|
(4,009
|
)
|
|
|
(4,398
|
)
|
|
|
|
|
|
|
Increase in other liabilities
|
|
|
4,548
|
|
|
|
5,999
|
|
|
|
|
|
Excess tax benefit on share-based compensation
|
|
|
(3,854
|
)
|
|
|
(3,357
|
)
|
|
|
|
|
Other sources
|
|
|
548
|
|
|
|
407
|
|
|
|
|
|
|
Net cash provided by operating activities
|
|
|
174,343
|
|
|
|
86,012
|
|
|
Cash Flows from Investing Activities
|
|
|
|
|
|
|
|
|
|
|
Capital expenditures
|
|
|
(29,592
|
)
|
|
|
(25,639
|
)
|
|
|
Business combinations, net of cash acquired
|
|
|
(3,664
|
)
|
|
|
(9,469
|
)
|
|
|
Other uses
|
|
|
(858
|
)
|
|
|
(592
|
)
|
|
|
|
|
Net cash used by investing activities
|
|
|
(34,114
|
)
|
|
|
(35,700
|
)
|
|
Cash Flows from Financing Activities
|
|
|
|
|
|
|
|
|
|
|
Purchases of treasury stock
|
|
|
(147,886
|
)
|
|
|
(109,330
|
)
|
|
|
Dividends paid
|
|
|
(12,538
|
)
|
|
|
(11,881
|
)
|
|
|
Proceeds from exercise of stock options
|
|
|
8,036
|
|
|
|
5,327
|
|
|
|
Excess tax benefit on share-based compensation
|
|
|
3,854
|
|
|
|
3,357
|
|
|
|
Debt issuance costs
|
|
|
(2,657
|
)
|
|
|
-
|
|
|
|
Increase/(decrease) in cash overdraft payable
|
|
|
(826
|
)
|
|
|
(581
|
)
|
|
|
Other sources
|
|
|
(48
|
)
|
|
|
297
|
|
|
|
|
|
Net cash used by financing activities
|
|
|
(152,065
|
)
|
|
|
(112,811
|
)
|
|
Increase/(Decrease) in Cash and Cash Equivalents
|
|
|
(11,836
|
)
|
|
|
(62,499
|
)
|
|
Cash and cash equivalents at beginning of year
|
|
|
49,917
|
|
|
|
112,416
|
|
|
Cash and cash equivalents at end of year
|
|
$
|
38,081
|
|
|
$
|
49,917
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CHEMED CORPORATION AND SUBSIDIARY COMPANIES
|
|
CONSOLIDATING STATEMENT OF INCOME
|
|
FOR THE THREE MONTHS ENDED DECEMBER 31, 2011 AND 2010
|
|
(in thousands)(unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Chemed
|
|
|
|
|
|
VITAS
|
|
Roto-Rooter
|
|
Corporate
|
|
Consolidated
|
|
2011
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Service revenues and sales
|
|
|
$
|
254,560
|
|
|
$
|
95,693
|
|
|
$
|
-
|
|
|
$
|
350,253
|
|
|
Cost of services provided and goods sold
|
|
|
|
196,084
|
|
|
|
52,282
|
|
|
|
-
|
|
|
|
248,366
|
|
|
Selling, general and administrative expenses (a)
|
|
|
|
18,306
|
|
|
|
26,347
|
|
|
|
3,911
|
|
|
|
48,564
|
|
|
Depreciation
|
|
|
|
4,094
|
|
|
|
2,063
|
|
|
|
131
|
|
|
|
6,288
|
|
|
Amortization
|
|
|
|
384
|
|
|
|
156
|
|
|
|
469
|
|
|
|
1,009
|
|
|
|
Total costs and expenses
|
|
|
|
218,868
|
|
|
|
80,848
|
|
|
|
4,511
|
|
|
|
304,227
|
|
|
|
Income/(loss) from operations
|
|
|
|
35,692
|
|
|
|
14,845
|
|
|
|
(4,511
|
)
|
|
|
46,026
|
|
|
Interest expense (a)
|
|
|
|
(57
|
)
|
|
|
(84
|
)
|
|
|
(3,487
|
)
|
|
|
(3,628
|
)
|
|
Intercompany interest income/(expense)
|
|
|
|
735
|
|
|
|
394
|
|
|
|
(1,129
|
)
|
|
|
-
|
|
|
Other income/(expense)-net
|
|
|
|
59
|
|
|
|
(233
|
)
|
|
|
10
|
|
|
|
(164
|
)
|
|
|
Income/(loss) before income taxes
|
|
|
|
36,429
|
|
|
|
14,922
|
|
|
|
(9,117
|
)
|
|
|
42,234
|
|
|
Income taxes (a)
|
|
|
|
(13,755
|
)
|
|
|
(5,661
|
)
|
|
|
2,887
|
|
|
|
(16,529
|
)
|
|
|
Net income/(loss)
|
|
|
$
|
22,674
|
|
|
$
|
9,261
|
|
|
$
|
(6,230
|
)
|
|
$
|
25,705
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2010
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Service revenues and sales
|
|
|
$
|
242,268
|
|
|
$
|
94,018
|
|
|
$
|
-
|
|
|
$
|
336,286
|
|
|
Cost of services provided and goods sold
|
|
|
|
181,747
|
|
|
|
53,515
|
|
|
|
-
|
|
|
|
235,262
|
|
|
Selling, general and administrative expenses (b)
|
|
|
|
18,836
|
|
|
|
27,208
|
|
|
|
9,226
|
|
|
|
55,270
|
|
|
Depreciation
|
|
|
|
4,252
|
|
|
|
1,949
|
|
|
|
137
|
|
|
|
6,338
|
|
|
Amortization
|
|
|
|
486
|
|
|
|
126
|
|
|
|
338
|
|
|
|
950
|
|
|
|
Total costs and expenses
|
|
|
|
205,321
|
|
|
|
82,798
|
|
|
|
9,701
|
|
|
|
297,820
|
|
|
|
Income/(loss) from operations
|
|
|
|
36,947
|
|
|
|
11,220
|
|
|
|
(9,701
|
)
|
|
|
38,466
|
|
|
Interest expense (b)
|
|
|
|
(4
|
)
|
|
|
(46
|
)
|
|
|
(2,963
|
)
|
|
|
(3,013
|
)
|
|
Intercompany interest income/(expense)
|
|
|
|
854
|
|
|
|
486
|
|
|
|
(1,340
|
)
|
|
|
-
|
|
|
Other income/(expense)-net
|
|
|
|
(80
|
)
|
|
|
18
|
|
|
|
1,912
|
|
|
|
1,850
|
|
|
|
Income/(loss) before income taxes
|
|
|
|
37,717
|
|
|
|
11,678
|
|
|
|
(12,092
|
)
|
|
|
37,303
|
|
|
Income taxes (b)
|
|
|
|
(14,445
|
)
|
|
|
(4,421
|
)
|
|
|
4,193
|
|
|
|
(14,673
|
)
|
|
|
Net income/(loss)
|
|
|
$
|
23,272
|
|
|
$
|
7,257
|
|
|
$
|
(7,899
|
)
|
|
$
|
22,630
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The "Footnotes to Financial Statements" are integral parts of this
financial information.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CHEMED CORPORATION AND SUBSIDIARY COMPANIES
|
|
CONSOLIDATING STATEMENT OF INCOME
|
|
FOR THE YEARS ENDED DECEMBER 31, 2011 AND 2010
|
|
(in thousands)(unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Chemed
|
|
|
|
|
|
VITAS
|
|
Roto-Rooter
|
|
Corporate
|
|
Consolidated
|
|
2011
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Service revenues and sales
|
|
|
$
|
986,272
|
|
|
$
|
369,698
|
|
|
$
|
-
|
|
|
$
|
1,355,970
|
|
|
Cost of services provided and goods sold
|
|
|
|
766,732
|
|
|
|
203,752
|
|
|
|
-
|
|
|
|
970,484
|
|
|
Selling, general and administrative expenses (a)
|
|
|
|
75,698
|
|
|
|
102,528
|
|
|
|
24,034
|
|
|
|
202,260
|
|
|
Depreciation
|
|
|
|
16,583
|
|
|
|
8,130
|
|
|
|
534
|
|
|
|
25,247
|
|
|
Amortization
|
|
|
|
1,897
|
|
|
|
599
|
|
|
|
1,756
|
|
|
|
4,252
|
|
|
|
Total costs and expenses
|
|
|
|
860,910
|
|
|
|
315,009
|
|
|
|
26,324
|
|
|
|
1,202,243
|
|
|
|
Income/(loss) from operations
|
|
|
|
125,362
|
|
|
|
54,689
|
|
|
|
(26,324
|
)
|
|
|
153,727
|
|
|
Interest expense (a)
|
|
|
|
(229
|
)
|
|
|
(358
|
)
|
|
|
(13,301
|
)
|
|
|
(13,888
|
)
|
|
Intercompany interest income/(expense)
|
|
|
|
3,998
|
|
|
|
2,136
|
|
|
|
(6,134
|
)
|
|
|
-
|
|
|
Other income/(expense)-net
|
|
|
|
62
|
|
|
|
(235
|
)
|
|
|
890
|
|
|
|
717
|
|
|
|
Income/(loss) before income taxes
|
|
|
|
129,193
|
|
|
|
56,232
|
|
|
|
(44,869
|
)
|
|
|
140,556
|
|
|
Income taxes (a)
|
|
|
|
(48,835
|
)
|
|
|
(21,353
|
)
|
|
|
15,611
|
|
|
|
(54,577
|
)
|
|
|
Net income/(loss)
|
|
|
$
|
80,358
|
|
|
$
|
34,879
|
|
|
$
|
(29,258
|
)
|
|
$
|
85,979
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2010
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Service revenues and sales
|
|
|
$
|
925,810
|
|
|
$
|
354,735
|
|
|
$
|
-
|
|
|
$
|
1,280,545
|
|
|
Cost of services provided and goods sold
|
|
|
|
709,094
|
|
|
|
196,922
|
|
|
|
-
|
|
|
|
906,016
|
|
|
Selling, general and administrative expenses (b)
|
|
|
|
73,755
|
|
|
|
100,731
|
|
|
|
27,478
|
|
|
|
201,964
|
|
|
Depreciation
|
|
|
|
16,161
|
|
|
|
7,775
|
|
|
|
450
|
|
|
|
24,386
|
|
|
Amortization
|
|
|
|
2,739
|
|
|
|
514
|
|
|
|
1,404
|
|
|
|
4,657
|
|
|
|
Total costs and expenses
|
|
|
|
801,749
|
|
|
|
305,942
|
|
|
|
29,332
|
|
|
|
1,137,023
|
|
|
|
Income/(loss) from operations
|
|
|
|
124,061
|
|
|
|
48,793
|
|
|
|
(29,332
|
)
|
|
|
143,522
|
|
|
Interest expense (b)
|
|
|
|
(131
|
)
|
|
|
(233
|
)
|
|
|
(11,595
|
)
|
|
|
(11,959
|
)
|
|
Intercompany interest income/(expense)
|
|
|
|
4,632
|
|
|
|
2,612
|
|
|
|
(7,244
|
)
|
|
|
-
|
|
|
Other income/(expense)-net
|
|
|
|
(165
|
)
|
|
|
53
|
|
|
|
2,380
|
|
|
|
2,268
|
|
|
|
Income/(loss) before income taxes
|
|
|
|
128,397
|
|
|
|
51,225
|
|
|
|
(45,791
|
)
|
|
|
133,831
|
|
|
Income taxes (b)
|
|
|
|
(48,601
|
)
|
|
|
(19,547
|
)
|
|
|
16,148
|
|
|
|
(52,000
|
)
|
|
|
Net income/(loss)
|
|
|
$
|
79,796
|
|
|
$
|
31,678
|
|
|
$
|
(29,643
|
)
|
|
$
|
81,831
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The "Footnotes to Financial Statements" are integral parts of this
financial information.
|
|
|
|
|
|
|
|
|
|
CHEMED CORPORATION AND SUBSIDIARY COMPANIES
|
|
CONSOLIDATING SUMMARY OF EBITDA
|
|
FOR THE THREE MONTHS ENDED DECEMBER 31, 2011 AND 2010
|
|
(in thousands)(unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Chemed
|
|
|
|
|
|
|
|
VITAS
|
|
Roto-Rooter
|
|
Corporate
|
|
Consolidated
|
|
2011
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income/(loss)
|
|
|
$
|
22,674
|
|
|
$
|
9,261
|
|
|
$
|
(6,230
|
)
|
|
$
|
25,705
|
|
|
Add/(deduct):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense
|
|
|
|
57
|
|
|
|
84
|
|
|
|
3,487
|
|
|
|
3,628
|
|
|
|
|
Income taxes
|
|
|
|
13,755
|
|
|
|
5,661
|
|
|
|
(2,887
|
)
|
|
|
16,529
|
|
|
|
|
Depreciation
|
|
|
|
4,094
|
|
|
|
2,063
|
|
|
|
131
|
|
|
|
6,288
|
|
|
|
|
Amortization
|
|
|
|
384
|
|
|
|
156
|
|
|
|
469
|
|
|
|
1,009
|
|
|
|
|
|
EBITDA
|
|
|
|
40,964
|
|
|
|
17,225
|
|
|
|
(5,030
|
)
|
|
|
53,159
|
|
|
Add/(deduct):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Intercompany interest expense/(income)
|
|
|
|
(735
|
)
|
|
|
(394
|
)
|
|
|
1,129
|
|
|
|
-
|
|
|
|
|
Interest income
|
|
|
|
(208
|
)
|
|
|
(12
|
)
|
|
|
(9
|
)
|
|
|
(229
|
)
|
|
|
|
Legal expenses of OIG investigation
|
|
|
|
(21
|
)
|
|
|
-
|
|
|
|
-
|
|
|
|
(21
|
)
|
|
|
|
Acquisition expenses
|
|
|
|
30
|
|
|
|
(20
|
)
|
|
|
-
|
|
|
|
10
|
|
|
|
|
Costs related to litigation settlements
|
|
|
|
-
|
|
|
|
848
|
|
|
|
-
|
|
|
|
848
|
|
|
|
|
Advertising cost adjustment (c)
|
|
|
|
-
|
|
|
|
202
|
|
|
|
-
|
|
|
|
202
|
|
|
|
|
Stock option expense
|
|
|
|
-
|
|
|
|
-
|
|
|
|
1,473
|
|
|
|
1,473
|
|
|
|
|
|
Adjusted EBITDA
|
|
|
$
|
40,030
|
|
|
$
|
17,849
|
|
|
$
|
(2,437
|
)
|
|
$
|
55,442
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2010
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income/(loss)
|
|
|
$
|
23,272
|
|
|
$
|
7,257
|
|
|
$
|
(7,899
|
)
|
|
$
|
22,630
|
|
|
Add/(deduct):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense
|
|
|
|
4
|
|
|
|
46
|
|
|
|
2,963
|
|
|
|
3,013
|
|
|
|
|
Income taxes
|
|
|
|
14,445
|
|
|
|
4,421
|
|
|
|
(4,193
|
)
|
|
|
14,673
|
|
|
|
|
Depreciation
|
|
|
|
4,252
|
|
|
|
1,949
|
|
|
|
137
|
|
|
|
6,338
|
|
|
|
|
Amortization
|
|
|
|
486
|
|
|
|
126
|
|
|
|
338
|
|
|
|
950
|
|
|
|
|
|
EBITDA
|
|
|
|
42,459
|
|
|
|
13,799
|
|
|
|
(8,654
|
)
|
|
|
47,604
|
|
|
Add/(deduct):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Intercompany interest expense/(income)
|
|
|
|
(854
|
)
|
|
|
(486
|
)
|
|
|
1,340
|
|
|
|
-
|
|
|
|
|
Interest income
|
|
|
|
(48
|
)
|
|
|
(12
|
)
|
|
|
(50
|
)
|
|
|
(110
|
)
|
|
|
|
Legal expenses of OIG investigation
|
|
|
|
622
|
|
|
|
-
|
|
|
|
-
|
|
|
|
622
|
|
|
|
|
Acquisition expenses
|
|
|
|
68
|
|
|
|
256
|
|
|
|
-
|
|
|
|
324
|
|
|
|
|
Costs related to litigation settlements
|
|
|
|
-
|
|
|
|
1,426
|
|
|
|
-
|
|
|
|
1,426
|
|
|
|
|
Advertising cost adjustment (c)
|
|
|
|
-
|
|
|
|
960
|
|
|
|
-
|
|
|
|
960
|
|
|
|
|
Long-term incentive compensation
|
|
|
|
-
|
|
|
|
-
|
|
|
|
2,935
|
|
|
|
2,935
|
|
|
|
|
Stock option expense
|
|
|
|
-
|
|
|
|
-
|
|
|
|
1,397
|
|
|
|
1,397
|
|
|
|
|
|
Adjusted EBITDA
|
|
|
$
|
42,247
|
|
|
$
|
15,943
|
|
|
$
|
(3,032
|
)
|
|
$
|
55,158
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The "Footnotes to Financial Statements" are integral parts of this
financial information.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CHEMED CORPORATION AND SUBSIDIARY COMPANIES
|
|
CONSOLIDATING SUMMARY OF EBITDA
|
|
FOR THE YEARS ENDED DECEMBER 31, 2011 AND 2010
|
|
(in thousands)(unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Chemed
|
|
|
|
|
|
|
|
VITAS
|
|
Roto-Rooter
|
|
Corporate
|
|
Consolidated
|
|
2011
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income/(loss)
|
|
|
$
|
80,358
|
|
|
$
|
34,879
|
|
|
$
|
(29,258
|
)
|
|
$
|
85,979
|
|
|
Add/(deduct):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense
|
|
|
|
229
|
|
|
|
358
|
|
|
|
13,301
|
|
|
|
13,888
|
|
|
|
|
Income taxes
|
|
|
|
48,835
|
|
|
|
21,353
|
|
|
|
(15,611
|
)
|
|
|
54,577
|
|
|
|
|
Depreciation
|
|
|
|
16,583
|
|
|
|
8,130
|
|
|
|
534
|
|
|
|
25,247
|
|
|
|
|
Amortization
|
|
|
|
1,897
|
|
|
|
599
|
|
|
|
1,756
|
|
|
|
4,252
|
|
|
|
|
|
EBITDA
|
|
|
|
147,902
|
|
|
|
65,319
|
|
|
|
(29,278
|
)
|
|
|
183,943
|
|
|
Add/(deduct):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Intercompany interest expense/(income)
|
|
|
|
(3,998
|
)
|
|
|
(2,136
|
)
|
|
|
6,134
|
|
|
|
-
|
|
|
|
|
Interest income
|
|
|
|
(295
|
)
|
|
|
(40
|
)
|
|
|
(91
|
)
|
|
|
(426
|
)
|
|
|
|
Legal expenses of OIG investigation
|
|
|
|
1,188
|
|
|
|
-
|
|
|
|
-
|
|
|
|
1,188
|
|
|
|
|
Acquisition expenses
|
|
|
|
147
|
|
|
|
(26
|
)
|
|
|
-
|
|
|
|
121
|
|
|
|
|
Costs related to litigation settlements
|
|
|
|
-
|
|
|
|
2,299
|
|
|
|
-
|
|
|
|
2,299
|
|
|
|
|
Advertising cost adjustment (c)
|
|
|
|
-
|
|
|
|
(1,240
|
)
|
|
|
-
|
|
|
|
(1,240
|
)
|
|
|
|
Stock option expense
|
|
|
|
-
|
|
|
|
-
|
|
|
|
8,376
|
|
|
|
8,376
|
|
|
|
|
Long-term incentive compensation
|
|
|
|
-
|
|
|
|
-
|
|
|
|
3,012
|
|
|
|
3,012
|
|
|
|
|
|
Adjusted EBITDA
|
|
|
$
|
144,944
|
|
|
$
|
64,176
|
|
|
$
|
(11,847
|
)
|
|
$
|
197,273
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2010
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income/(loss)
|
|
|
$
|
79,796
|
|
|
$
|
31,678
|
|
|
$
|
(29,643
|
)
|
|
$
|
81,831
|
|
|
Add/(deduct):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense
|
|
|
|
131
|
|
|
|
233
|
|
|
|
11,595
|
|
|
|
11,959
|
|
|
|
|
Income taxes
|
|
|
|
48,601
|
|
|
|
19,547
|
|
|
|
(16,148
|
)
|
|
|
52,000
|
|
|
|
|
Depreciation
|
|
|
|
16,161
|
|
|
|
7,775
|
|
|
|
450
|
|
|
|
24,386
|
|
|
|
|
Amortization
|
|
|
|
2,739
|
|
|
|
514
|
|
|
|
1,404
|
|
|
|
4,657
|
|
|
|
|
|
EBITDA
|
|
|
|
147,428
|
|
|
|
59,747
|
|
|
|
(32,342
|
)
|
|
|
174,833
|
|
|
Add/(deduct):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Intercompany interest expense/(income)
|
|
|
|
(4,632
|
)
|
|
|
(2,612
|
)
|
|
|
7,244
|
|
|
|
-
|
|
|
|
|
Interest income
|
|
|
|
(220
|
)
|
|
|
(49
|
)
|
|
|
(175
|
)
|
|
|
(444
|
)
|
|
|
|
Legal expenses of OIG investigation
|
|
|
|
1,012
|
|
|
|
-
|
|
|
|
-
|
|
|
|
1,012
|
|
|
|
|
Acquisition expenses
|
|
|
|
68
|
|
|
|
256
|
|
|
|
-
|
|
|
|
324
|
|
|
|
|
Costs related to litigation settlements
|
|
|
|
-
|
|
|
|
1,853
|
|
|
|
-
|
|
|
|
1,853
|
|
|
|
|
Advertising cost adjustment (c)
|
|
|
|
-
|
|
|
|
(679
|
)
|
|
|
-
|
|
|
|
(679
|
)
|
|
|
|
Stock option expense
|
|
|
|
-
|
|
|
|
-
|
|
|
|
7,762
|
|
|
|
7,762
|
|
|
|
|
Long-term incentive compensation
|
|
|
|
-
|
|
|
|
-
|
|
|
|
4,734
|
|
|
|
4,734
|
|
|
|
|
|
Adjusted EBITDA
|
|
|
$
|
143,656
|
|
|
$
|
58,516
|
|
|
$
|
(12,777
|
)
|
|
$
|
189,395
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The "Footnotes to Financial Statements" are integral parts of this
financial information.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CHEMED CORPORATION AND SUBSIDIARY COMPANIES
|
|
RECONCILIATION OF ADJUSTED NET INCOME
|
|
(in thousands, except per share data)(unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Three Months Ended
|
|
|
For the Years Ended
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
|
December 31,
|
|
|
|
|
|
|
|
|
|
2011
|
|
2010
|
|
|
2011
|
|
2010
|
|
Net income as reported
|
|
|
|
|
$
|
25,705
|
|
|
$
|
22,630
|
|
|
$
|
85,979
|
|
$
|
81,831
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Add/(deduct) impact of:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
After-tax additional interest expense resulting from the change in
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
accounting for the conversion feature of the convertible notes
|
|
|
|
|
|
1,200
|
|
|
|
1,110
|
|
|
|
4,664
|
|
|
4,313
|
|
|
|
After-tax stock option expense
|
|
|
|
|
|
932
|
|
|
|
883
|
|
|
|
5,298
|
|
|
4,909
|
|
|
|
After-tax cost of costs related to litigation settlements
|
|
|
|
|
|
516
|
|
|
|
869
|
|
|
|
1,397
|
|
|
1,126
|
|
|
|
After-tax cost of legal expenses of OIG investigation
|
|
|
|
|
|
(12
|
)
|
|
|
385
|
|
|
|
737
|
|
|
627
|
|
|
|
After-tax cost of acquisition expenses
|
|
|
|
|
|
6
|
|
|
|
198
|
|
|
|
75
|
|
|
198
|
|
|
|
After-tax long-term incentive compensation
|
|
|
|
|
|
-
|
|
|
|
1,833
|
|
|
|
1,880
|
|
|
2,957
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted net income
|
|
|
|
|
$
|
28,347
|
|
|
$
|
27,908
|
|
|
$
|
100,030
|
|
$
|
95,961
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings Per Share As Reported
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
|
|
|
$
|
1.34
|
|
|
$
|
1.00
|
|
|
$
|
4.19
|
|
$
|
3.62
|
|
|
|
Average number of shares outstanding
|
|
|
|
|
|
19,237
|
|
|
|
22,534
|
|
|
|
20,523
|
|
|
22,587
|
|
Diluted Earnings Per Share As Reported
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
|
|
|
$
|
1.31
|
|
|
$
|
0.98
|
|
|
$
|
4.10
|
|
$
|
3.55
|
|
|
|
Average number of shares outstanding
|
|
|
|
|
|
19,556
|
|
|
|
23,070
|
|
|
|
20,945
|
|
|
23,031
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted Earnings Per Share
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
|
|
|
$
|
1.47
|
|
|
$
|
1.24
|
|
|
$
|
4.87
|
|
$
|
4.25
|
|
|
|
Average number of shares outstanding
|
|
|
|
|
|
19,237
|
|
|
|
22,534
|
|
|
|
20,523
|
|
|
22,587
|
|
Adjusted Diluted Earnings Per Share
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
|
|
|
$
|
1.45
|
|
|
$
|
1.21
|
|
|
$
|
4.78
|
|
$
|
4.17
|
|
|
|
Average number of shares outstanding
|
|
|
|
|
|
19,556
|
|
|
|
23,070
|
|
|
|
20,945
|
|
|
23,031
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The "Footnotes to Financial Statements" are integral parts of this
financial information.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CHEMED CORPORATION AND SUBSIDIARY COMPANIES
|
|
|
OPERATING STATISTICS FOR VITAS SEGMENT
|
|
|
(unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Three Months Ended
|
|
|
For the Years Ended
|
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
|
December 31,
|
|
|
OPERATING STATISTICS
|
|
|
|
|
2011
|
|
|
2010
|
|
|
2011
|
|
|
2010
|
|
|
|
Net revenue ($000) (d)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Homecare
|
|
|
|
|
$
|
188,782
|
|
|
|
$
|
176,517
|
|
|
|
$
|
718,658
|
|
|
|
$
|
666,562
|
|
|
|
|
|
Inpatient
|
|
|
|
|
|
27,882
|
|
|
|
|
27,344
|
|
|
|
|
110,742
|
|
|
|
|
105,588
|
|
|
|
|
|
Continuous care
|
|
|
|
|
|
40,516
|
|
|
|
|
39,463
|
|
|
|
|
158,466
|
|
|
|
|
153,050
|
|
|
|
|
|
|
Total before Medicare cap allowance
|
|
|
|
|
$
|
257,180
|
|
|
|
$
|
243,324
|
|
|
|
$
|
987,866
|
|
|
|
$
|
925,200
|
|
|
|
|
|
Medicare cap allowance
|
|
|
|
|
|
(2,620
|
)
|
|
|
|
(1,056
|
)
|
|
|
|
(1,594
|
)
|
|
|
|
610
|
|
|
|
|
|
|
Total
|
|
|
|
|
$
|
254,560
|
|
|
|
$
|
242,268
|
|
|
|
$
|
986,272
|
|
|
|
$
|
925,810
|
|
|
|
|
Net revenue as a percent of total before Medicare cap allowance
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Homecare
|
|
|
|
|
|
73.4
|
|
%
|
|
|
72.6
|
|
%
|
|
|
72.7
|
|
%
|
|
|
72.0
|
|
%
|
|
|
|
Inpatient
|
|
|
|
|
|
10.8
|
|
|
|
|
11.2
|
|
|
|
|
11.2
|
|
|
|
|
11.4
|
|
|
|
|
|
Continuous care
|
|
|
|
|
|
15.8
|
|
|
|
|
16.2
|
|
|
|
|
16.1
|
|
|
|
|
16.6
|
|
|
|
|
|
|
Total before Medicare cap allowance
|
|
|
|
|
|
100.0
|
|
|
|
|
100.0
|
|
|
|
|
100.0
|
|
|
|
|
100.0
|
|
|
|
|
|
Medicare cap allowance
|
|
|
|
|
|
(1.0
|
)
|
|
|
|
(0.4
|
)
|
|
|
|
(0.2
|
)
|
|
|
|
(0.1
|
)
|
|
|
|
|
|
Total
|
|
|
|
|
|
99.0
|
|
%
|
|
|
99.6
|
|
%
|
|
|
99.8
|
|
%
|
|
|
99.9
|
|
%
|
|
|
Average daily census ("ADC") (days)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Homecare
|
|
|
|
|
|
9,582
|
|
|
|
|
8,851
|
|
|
|
|
9,285
|
|
|
|
|
8,476
|
|
|
|
|
|
Nursing home
|
|
|
|
|
|
3,092
|
|
|
|
|
3,193
|
|
|
|
|
3,069
|
|
|
|
|
3,207
|
|
|
|
|
|
|
Routine homecare
|
|
|
|
|
|
12,674
|
|
|
|
|
12,044
|
|
|
|
|
12,354
|
|
|
|
|
11,683
|
|
|
|
|
|
Inpatient
|
|
|
|
|
|
443
|
|
|
|
|
436
|
|
|
|
|
449
|
|
|
|
|
434
|
|
|
|
|
|
Continuous care
|
|
|
|
|
|
607
|
|
|
|
|
600
|
|
|
|
|
603
|
|
|
|
|
596
|
|
|
|
|
|
|
Total
|
|
|
|
|
|
13,724
|
|
|
|
|
13,080
|
|
|
|
|
13,406
|
|
|
|
|
12,713
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Admissions
|
|
|
|
|
|
15,191
|
|
|
|
|
14,776
|
|
|
|
|
60,162
|
|
|
|
|
58,526
|
|
|
|
|
Total Discharges
|
|
|
|
|
|
15,289
|
|
|
|
|
15,038
|
|
|
|
|
60,393
|
|
|
|
|
57,817
|
|
|
|
|
Average length of stay (days)
|
|
|
|
|
|
79.0
|
|
|
|
|
80.8
|
|
|
|
|
78.8
|
|
|
|
|
78.1
|
|
|
|
|
Median length of stay (days)
|
|
|
|
|
|
14.0
|
|
|
|
|
15.0
|
|
|
|
|
14.0
|
|
|
|
|
14.0
|
|
|
|
|
ADC by major diagnosis
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Neurological
|
|
|
|
|
|
34.0
|
|
%
|
|
|
33.9
|
|
%
|
|
|
34.4
|
|
%
|
|
|
33.6
|
|
%
|
|
|
|
Cancer
|
|
|
|
|
|
17.8
|
|
|
|
|
18.3
|
|
|
|
|
17.7
|
|
|
|
|
18.4
|
|
|
|
|
|
Cardio
|
|
|
|
|
|
11.3
|
|
|
|
|
11.7
|
|
|
|
|
11.5
|
|
|
|
|
11.9
|
|
|
|
|
|
Respiratory
|
|
|
|
|
|
6.4
|
|
|
|
|
6.6
|
|
|
|
|
6.7
|
|
|
|
|
6.6
|
|
|
|
|
|
Other
|
|
|
|
|
|
30.5
|
|
|
|
|
29.5
|
|
|
|
|
29.7
|
|
|
|
|
29.5
|
|
|
|
|
|
|
Total
|
|
|
|
|
|
100.0
|
|
%
|
|
|
100.0
|
|
%
|
|
|
100.0
|
|
%
|
|
|
100.0
|
|
%
|
|
|
Admissions by major diagnosis
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Neurological
|
|
|
|
|
|
19.4
|
|
%
|
|
|
19.5
|
|
%
|
|
|
19.4
|
|
%
|
|
|
18.8
|
|
%
|
|
|
|
Cancer
|
|
|
|
|
|
34.4
|
|
|
|
|
34.4
|
|
|
|
|
33.5
|
|
|
|
|
34.5
|
|
|
|
|
|
Cardio
|
|
|
|
|
|
10.8
|
|
|
|
|
11.0
|
|
|
|
|
10.8
|
|
|
|
|
11.3
|
|
|
|
|
|
Respiratory
|
|
|
|
|
|
7.6
|
|
|
|
|
7.4
|
|
|
|
|
8.3
|
|
|
|
|
8.0
|
|
|
|
|
|
Other
|
|
|
|
|
|
27.8
|
|
|
|
|
27.7
|
|
|
|
|
28.0
|
|
|
|
|
27.4
|
|
|
|
|
|
|
Total
|
|
|
|
|
|
100.0
|
|
%
|
|
|
100.0
|
|
%
|
|
|
100.0
|
|
%
|
|
|
100.0
|
|
%
|
|
|
Direct patient care margins (e)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Routine homecare
|
|
|
|
|
|
53.2
|
|
%
|
|
|
54.0
|
|
%
|
|
|
52.3
|
|
%
|
|
|
52.8
|
|
%
|
|
|
|
Inpatient
|
|
|
|
|
|
13.1
|
|
|
|
|
14.4
|
|
|
|
|
12.9
|
|
|
|
|
13.6
|
|
|
|
|
|
Continuous care
|
|
|
|
|
|
19.9
|
|
|
|
|
22.6
|
|
|
|
|
20.3
|
|
|
|
|
21.4
|
|
|
|
|
Homecare margin drivers (dollars per patient day)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Labor costs
|
|
|
|
|
$
|
52.92
|
|
|
|
$
|
51.97
|
|
|
|
$
|
53.63
|
|
|
|
$
|
52.57
|
|
|
|
|
|
Drug costs
|
|
|
|
|
|
8.31
|
|
|
|
|
7.89
|
|
|
|
|
8.19
|
|
|
|
|
7.81
|
|
|
|
|
|
Home medical equipment
|
|
|
|
|
|
6.78
|
|
|
|
|
5.84
|
|
|
|
|
6.69
|
|
|
|
|
6.48
|
|
|
|
|
|
Medical supplies
|
|
|
|
|
|
2.79
|
|
|
|
|
2.67
|
|
|
|
|
2.80
|
|
|
|
|
2.56
|
|
|
|
|
Inpatient margin drivers (dollars per patient day)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Labor costs
|
|
|
|
|
$
|
320.43
|
|
|
|
$
|
305.19
|
|
|
|
$
|
312.78
|
|
|
|
$
|
299.54
|
|
|
|
|
Continuous care margin drivers (dollars per patient day)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Labor costs
|
|
|
|
|
$
|
559.11
|
|
|
|
$
|
533.32
|
|
|
|
$
|
552.38
|
|
|
|
$
|
531.69
|
|
|
|
|
Bad debt expense as a percent of revenues
|
|
|
|
|
|
0.6
|
|
%
|
|
|
0.7
|
|
%
|
|
|
0.7
|
|
%
|
|
|
0.9
|
|
%
|
|
|
Accounts receivable --
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Days of revenue outstanding- excluding unapplied Medicare payments
|
|
|
|
|
|
36.7
|
|
|
|
|
38.2
|
|
|
|
|
n.a.
|
|
|
|
n.a.
|
|
|
|
Days of revenue outstanding- including unapplied Medicare payments
|
|
|
|
|
|
22.3
|
|
|
|
|
36.5
|
|
|
|
|
n.a.
|
|
|
|
n.a.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The "Footnotes to Financial Statements" are integral parts of this
financial information.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CHEMED CORPORATION AND SUBSIDIARY COMPANIES
|
|
FOOTNOTES TO FINANCIAL STATEMENTS
|
|
FOR THE THREE MONTHS AND YEARS ENDED DECEMBER 31, 2011 AND 2010
|
|
(unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(a)
|
|
Included in the results of operations 2011 are the following
significant credits/(charges) which may not be indicative of
ongoing operations (in thousands):
|
|
|
|
|
|
|
|
|
For the Three Months Ended December 31, 2011
|
|
|
|
|
|
|
|
|
VITAS
|
|
Roto-Rooter
|
|
Corporate
|
|
Consolidated
|
|
|
|
Selling, general and administrative expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Legal expenses of OIG investigation
|
|
$
|
21
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
21
|
|
|
|
|
|
Acquisition expenses
|
|
|
(30
|
)
|
|
|
20
|
|
|
|
-
|
|
|
|
(10
|
)
|
|
|
|
|
Costs related to litigation settlements
|
|
|
-
|
|
|
|
(848
|
)
|
|
|
-
|
|
|
|
(848
|
)
|
|
|
|
|
Stock option expense
|
|
|
-
|
|
|
|
-
|
|
|
|
(1,473
|
)
|
|
|
(1,473
|
)
|
|
|
|
Interest expense:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Additional interest expense resulting from the change in accounting
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
for the conversion feature of the convertible notes
|
|
|
-
|
|
|
|
-
|
|
|
|
(1,898
|
)
|
|
|
(1,898
|
)
|
|
|
|
|
|
Pretax impact on earnings
|
|
|
(9
|
)
|
|
|
(828
|
)
|
|
|
(3,371
|
)
|
|
|
(4,208
|
)
|
|
|
|
Income tax benefit on the above
|
|
|
3
|
|
|
|
324
|
|
|
|
1,239
|
|
|
|
1,566
|
|
|
|
|
|
|
After-tax impact on earnings
|
|
$
|
(6
|
)
|
|
$
|
(504
|
)
|
|
$
|
(2,132
|
)
|
|
$
|
(2,642
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Years Ended December 31, 2011
|
|
|
|
|
|
|
|
|
VITAS
|
|
Roto-Rooter
|
|
Corporate
|
|
Consolidated
|
|
|
|
Selling, general and administrative expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Legal expenses of OIG investigation
|
|
$
|
(1,188
|
)
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
(1,188
|
)
|
|
|
|
|
Acquisition expenses
|
|
|
(147
|
)
|
|
|
26
|
|
|
|
-
|
|
|
|
(121
|
)
|
|
|
|
|
Costs related to litigation settlements
|
|
|
-
|
|
|
|
(2,299
|
)
|
|
|
-
|
|
|
|
(2,299
|
)
|
|
|
|
|
Stock option expense
|
|
|
-
|
|
|
|
-
|
|
|
|
(8,376
|
)
|
|
|
(8,376
|
)
|
|
|
|
|
Long-term incentive compensation
|
|
|
-
|
|
|
|
-
|
|
|
|
(3,012
|
)
|
|
|
(3,012
|
)
|
|
|
|
Interest expense:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Additional interest expense resulting from the change in accounting
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
for the conversion feature of the convertible notes
|
|
|
-
|
|
|
|
-
|
|
|
|
(7,374
|
)
|
|
|
(7,374
|
)
|
|
|
|
|
|
Pretax impact on earnings
|
|
|
(1,335
|
)
|
|
|
(2,273
|
)
|
|
|
(18,762
|
)
|
|
|
(22,370
|
)
|
|
|
|
Income tax benefit on the above
|
|
|
507
|
|
|
|
892
|
|
|
|
6,920
|
|
|
|
8,319
|
|
|
|
|
|
|
After-tax impact on earnings
|
|
$
|
(828
|
)
|
|
$
|
(1,381
|
)
|
|
$
|
(11,842
|
)
|
|
$
|
(14,051
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(b)
|
|
Included in the results of operations 2010 are the following
significant credits/(charges) which may not be indicative of
ongoing operations (in thousands):
|
|
|
|
|
|
|
|
|
For the Three Months Ended December 31, 2010
|
|
|
|
|
|
|
|
|
VITAS
|
|
Roto-Rooter
|
|
Corporate
|
|
Consolidated
|
|
|
|
Selling, general and administrative expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Legal expenses of OIG investigation
|
|
$
|
(622
|
)
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
(622
|
)
|
|
|
|
|
Acquisition expenses
|
|
|
(68
|
)
|
|
|
(256
|
)
|
|
|
-
|
|
|
|
(324
|
)
|
|
|
|
|
Costs related to litigation settlements
|
|
|
-
|
|
|
|
(1,426
|
)
|
|
|
-
|
|
|
|
(1,426
|
)
|
|
|
|
|
Long-term incentive compensation
|
|
|
-
|
|
|
|
-
|
|
|
|
(2,935
|
)
|
|
|
(2,935
|
)
|
|
|
|
|
Stock option expense
|
|
|
-
|
|
|
|
-
|
|
|
|
(1,397
|
)
|
|
|
(1,397
|
)
|
|
|
|
Interest expense:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Additional interest expense resulting from the change in accounting
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
for the conversion feature of the convertible notes
|
|
|
-
|
|
|
|
-
|
|
|
|
(1,756
|
)
|
|
|
(1,756
|
)
|
|
|
|
|
|
Pretax impact on earnings
|
|
|
(690
|
)
|
|
|
(1,682
|
)
|
|
|
(6,088
|
)
|
|
|
(8,460
|
)
|
|
|
|
Income tax benefit on the above
|
|
|
263
|
|
|
|
657
|
|
|
|
2,262
|
|
|
|
3,182
|
|
|
|
|
|
|
After-tax impact on earnings
|
|
$
|
(427
|
)
|
|
$
|
(1,025
|
)
|
|
$
|
(3,826
|
)
|
|
$
|
(5,278
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Years Ended December 31, 2010
|
|
|
|
|
|
|
|
|
VITAS
|
|
Roto-Rooter
|
|
Corporate
|
|
Consolidated
|
|
|
|
Selling, general and administrative expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Legal expenses of OIG investigation
|
|
$
|
(1,012
|
)
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
(1,012
|
)
|
|
|
|
|
Acquisition expenses
|
|
|
(68
|
)
|
|
|
(256
|
)
|
|
|
-
|
|
|
|
(324
|
)
|
|
|
|
|
Costs related to litigation settlements
|
|
|
-
|
|
|
|
(1,853
|
)
|
|
|
-
|
|
|
|
(1,853
|
)
|
|
|
|
|
Stock option expense
|
|
|
-
|
|
|
|
-
|
|
|
|
(7,762
|
)
|
|
|
(7,762
|
)
|
|
|
|
|
Long-term incentive compensation
|
|
|
-
|
|
|
|
-
|
|
|
|
(4,734
|
)
|
|
|
(4,734
|
)
|
|
|
|
Interest expense:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Additional interest expense resulting from the change in accounting
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
for the conversion feature of the convertible notes
|
|
|
-
|
|
|
|
-
|
|
|
|
(6,820
|
)
|
|
|
(6,820
|
)
|
|
|
|
|
|
Pretax impact on earnings
|
|
|
(1,080
|
)
|
|
|
(2,109
|
)
|
|
|
(19,316
|
)
|
|
|
(22,505
|
)
|
|
|
|
Income tax benefit on the above
|
|
|
411
|
|
|
|
827
|
|
|
|
7,137
|
|
|
|
8,375
|
|
|
|
|
|
|
After-tax impact on earnings
|
|
$
|
(669
|
)
|
|
$
|
(1,282
|
)
|
|
$
|
(12,179
|
)
|
|
$
|
(14,130
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(c)
|
|
Under Generally Accepted Accounting Principles ("GAAP"), the
Roto-Rooter segment expenses all advertising, including the cost
of telephone directories, immediately upon the initial release of
the advertising. Telephone directories are generally in
circulation 12 months. If a directory is in circulation for a time
period greater or less than 12 months, the publisher adjusts the
directory billing for the change in billing period. The timing of
when a telephone directory is published can and does fluctuate
significantly on a quarterly basis. This "direct expensing"
results in significant fluctuations in quarterly advertising
expense. In the fourth quarters of 2011 and 2010, GAAP advertising
expense for Roto-Rooter totaled $6,073,000 and $7,034,000,
respectively. If the expense of the telephone directories were
spread over the periods they are in circulation, advertising
expense for the fourth quarters of 2011 and 2010 would total
$5,871,000 and $6,074,000, respectively.
|
|
|
|
|
|
|
|
Similarly, for the years ended December 31, 2011 and 2010, GAAP
advertising expense for Roto-Rooter totaled $22,534,000 and
$23,849,00, respectively. If the expense of the telephone
directories were spread over the periods they are in circulation,
advertising expense for years ended December 31, 2011 and 2010,
would total $23,774,000 and $24,528,000, respectively.
|
|
|
|
|
|
(d)
|
|
VITAS has 8 large (greater than 450 ADC), 16 medium (greater than
200 but less than 450 ADC) and 28 small (less than 200 ADC)
hospice programs. For the current cap year there are three
programs with a cap liabilities and six programs with Medicare cap
cushions of less than 10%.
|
|
|
|
|
|
(e)
|
|
Amounts exclude indirect patient care and administrative costs, as
well as Medicare Cap billing limitation.
|
|
|
|
|

[ Back To TMCnet.com's Homepage ]
|